Arthur F. Ryan, Director at REGENERON PHARMACEUTICALS, INC. (REGN), sold 100 shares at $898.76 ($90K) on 2024-01-02, disclosed to the SEC on 2024-01-04.
Scheduled sale ($90k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $873.91 | 1 | $874 | 1.0% |
| 2 | $886.26 | 2 | $2K | 2.0% |
| 3 | $887.13 | 1 | $887 | 1.0% |
| 4 | $892.00 | 1 | $892 | 1.0% |
| 5 | $896.47 | 8 | $7K | 8.0% |
| 6 | $897.41 | 3 |
| $3K |
| 3.0% |
| 7 | $898.76 | 6 | $5K | 6.0% |
| 8 | $899.66 | 14 | $13K | 14.0% |
| 9 | $900.59 | 29 | $26K | 29.0% |
| 10 | $901.46 | 9 | $8K | 9.0% |
| 11 | $902.37 | 10 | $9K | 10.0% |
| 12 | $903.49 | 13 | $12K | 13.1% |
| 13 | $904.49 | 3 | $3K | 3.0% |
| Total | $899.90 avg | 100 | $90K | 100% |
| Filing → |
| REGN | SELL | 2026-04-03 | $78K | — | Filing → |
| REGN | SELL | 2026-03-03 | $79K | — | Filing → |
| REGN | SELL | 2026-02-11 | $78K | — | Filing → |